Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group

Cancer Immunol Immunother. 2000 Sep;49(7):395-400. doi: 10.1007/s002620000128.


Background: Because of the known efficacy of several cytokines in the treatment of advanced renal cell cancer (RCC), we have conducted a phase II trial of the efficacy and toxicity of subcutaneous interferon gamma (IFNgamma) and interleukin-2 (IL-2).

Methods: 63 patients with progressive metastatic RCC were treated with 100 microg recombinant IFNgamma1b administered three times weekly during weeks 1 and 2 and with 4.5 MU recombinant IL-2 administered on 4 consecutive days during weeks 3 and 4, every 6 weeks.

Results: 11% of patients had an objective response (CR: 3%, PR: 8%), 33% had SD. Toxicity was generally mild. The median duration of remissions (CR + PR) was 9.6 months; the median duration of SD 8 months. A significant survival benefit was evident at a median observation time of 51 months for patients (44%) responding to therapy (P < 0.0001).

Conclusions: we conclude that sequential treatment with IFNgamma and IL-2 may prolong survival in patients with metastatic RCC responding to therapy.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Subcutaneous
  • Interferon-gamma / administration & dosage
  • Interferon-gamma / adverse effects
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / analogs & derivatives*
  • Kidney Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Recombinant Proteins / administration & dosage
  • Survival Analysis


  • Interleukin-2
  • Recombinant Proteins
  • Interferon-gamma
  • aldesleukin